HOME > REGULATORY
REGULATORY
- Guidance on Companion Diagnostics Calls for Inclusion of Biomarker-Negative Subjects in Clinical Studies
January 8, 2014
- MHLW Adds Precaution for Driving in Package Inserts of Donepezil and Other Drugs
January 8, 2014
- MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
- MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
- HSB Invites Additional Applicants for New Flu Vaccine Development and Production Project
January 7, 2014
- Discarded Plan to Institutionalize Key Premium Still Faces Backlash; Rough Sailing Expected before Next Reform
December 27, 2013
- Shiga University of Medical Science Wants to Correct Diovan Paper, Sent Data Found During Diovan Probe to US Journal
December 27, 2013
- Chuikyo Reps Slam Inter-Ministerial Deal to Scrap Insurance Coverage for Gargles
December 27, 2013
- Chuikyo Approves 60% Upper Limit for Evaluating Generic Drug Use at DPC Hospitals
December 27, 2013
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
- MHLW Pitches Dispensing Fee Cuts for Hospitals, Pharmacies with Low Price Settlement Rates
December 26, 2013
- Active Recommendation for HPV Vaccines Remains Suspended
December 26, 2013
- Gist of FY2014 NHI Price Revision
December 26, 2013
- Health Ministry to Request Hospitals to Inspect Clinical Studies Initiated between FY2000 and 2008
December 26, 2013
- Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
- Regulatory Reform Council Gives Directions for Expansion of Special Scheme for Mixed Healthcare, Yet No Concrete Plan
December 26, 2013
- Health Ministry Committee Decides Details of Drug Safety Evaluation after Rx-to-OTC Switches
December 26, 2013
- FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
- Government to Allocate 8,696 Million Yen in FY2014 Budget for Faster Drug Review, Pharma Business Revitalization
December 25, 2013
- FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…